 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Previous Article | Next Article
The Journal of Neuroscience, August 1, 2002, 22(15):6742-6746
Differential Activation of Orexin Neurons by Antipsychotic Drugs Associated with Weight Gain
Jim Fadel*, Michael Bubser*, and Ariel Y. Deutch Departments of Psychiatry and Pharmacology and Centers for Molecular Neuroscience and Integrative and Cognitive Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee 37212
Weight gain is one side effect of many antipsychotic drugs (APDs). A small number of lateral hypothalamic/perifornical area (LH/PFA) neurons express the orexins, peptides that are critically involved in body weight regulation and arousal. We examined the ability of APDs to activate orexin neurons, as reflected by induction of Fos. APDs with significant weight gain liability increased Fos expression in orexin neurons, but APDs with low or absent weight gain liability did not. The weight gain liability of APDs was correlated with the degree of Fos induction in orexin neurons of the lateral LH/PFA. In contrast, amphetamine, which causes weight loss, increased Fos expression in orexin neurons of the medial but not lateral LH/PFA. We compared the effects of amphetamine and clozapine, an APD with weight gain liability, on orexin neurons innervating the prefrontal cortex. Clozapine induced Fos in 75% of the orexin neurons that project to the cortex, but amphetamine induced Fos in less than a third of these cells. These data suggest that APD-induced weight gain is associated with activation of distinct orexin neurons and emphasize the presence of anatomically and functionally heterogeneous populations of orexin neurons.
Key words: amphetamine; clozapine; dopamine; haloperidol; prefrontal cortex; weight gain
* J.F. and M.B. contributed equally to this work.
Copyright © 2002 Society for Neuroscience 0270-6474/02/22156742-05$05.00/0
This article has been cited by other articles:
M. Robbins, H. Critchlow, A. Lloyd, J. Cilia, J. Clarke, B. Bond, D. Jones, and P. Maycox
Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT--PCR study
J Psychopharmacol, July 1, 2008; 22(5): 536 - 542.
[Abstract] [PDF]
S. Schwartz, A. Ponz, R. Poryazova, E. Werth, P. Boesiger, R. Khatami, and C. L. Bassetti
Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy
Brain, February 1, 2008; 131(2): 514 - 522.
[Abstract] [Full Text] [PDF]
C. S. McPherson, T. Featherby, E. Krstew, and J. L. Andrew
Quantification of Phosphorylated cAMP-Response Element-Binding Protein Expression throughout the Brain of Amphetamine-Sensitized Rats: Activation of Hypothalamic Orexin A-Containing Neurons
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 805 - 812.
[Abstract] [Full Text] [PDF]
E. K. Lambe, R.-J. Liu, and G. K. Aghajanian
Schizophrenia, Hypocretin (Orexin), and the Thalamocortical Activating System
Schizophr Bull, November 1, 2007; 33(6): 1284 - 1290.
[Abstract] [Full Text] [PDF]
K. Rasmussen, M.-A. Hsu, S. Noone, B. G. Johnson, L. K. Thompson, and S. K. Hemrick-Luecke
The Orexin-1 Antagonist SB-334867 Blocks Antipsychotic Treatment Emergent Catalepsy: Implications for the Treatment of Extrapyramidal Symptoms
Schizophr Bull, November 1, 2007; 33(6): 1291 - 1297.
[Abstract] [Full Text] [PDF]
A. Y. Deutch and M. Bubser
The Orexins/Hypocretins and Schizophrenia
Schizophr Bull, November 1, 2007; 33(6): 1277 - 1283.
[Abstract] [Full Text] [PDF]
C. O. Alberto, R. B. Trask, M. E. Quinlan, and M. Hirasawa
Bidirectional Dopaminergic Modulation of Excitatory Synaptic Transmission in Orexin Neurons
J. Neurosci., September 27, 2006; 26(39): 10043 - 10050.
[Abstract] [Full Text] [PDF]
G. P. Reynolds, M. J. Hill, and S. L. Kirk
The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics
J Psychopharmacol, July 1, 2006; 20(4_suppl): 15 - 18.
[Abstract] [PDF]
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1265 - 1277.
[Abstract] [Full Text] [PDF]
A. S. Levine, R. Winsky-Sommerer, S. Huitron-Resendiz, M. K. Grace, and L. de Lecea
Injection of neuropeptide W into paraventricular nucleus of hypothalamus increases food intake
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1727 - R1732.
[Abstract] [Full Text] [PDF]
E. K. Lambe, P. Olausson, N. K. Horst, J. R. Taylor, and G. K. Aghajanian
Hypocretin and Nicotine Excite the Same Thalamocortical Synapses in Prefrontal Cortex: Correlation with Improved Attention in Rat
J. Neurosci., May 25, 2005; 25(21): 5225 - 5229.
[Abstract] [Full Text] [PDF]
R. Winsky-Sommerer, A. Yamanaka, S. Diano, E. Borok, A. J. Roberts, T. Sakurai, T. S. Kilduff, T. L. Horvath, and L. de Lecea
Interaction between the Corticotropin-Releasing Factor System and Hypocretins (Orexins): A Novel Circuit Mediating Stress Response
J. Neurosci., December 15, 2004; 24(50): 11439 - 11448.
[Abstract] [Full Text] [PDF]
Y. Kayaba, A. Nakamura, Y. Kasuya, T. Ohuchi, M. Yanagisawa, I. Komuro, Y. Fukuda, and T. Kuwaki
Attenuated defense response and low basal blood pressure in orexin knockout mice
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R581 - R593.
[Abstract] [Full Text] [PDF]
H. Zheng, M. Corkern, I. Stoyanova, L. M. Patterson, R. Tian, and H.-R. Berthoud
Peptides that Regulate Food Intake: Appetite-inducing accumbens manipulation activates hypothalamic orexin neurons and inhibits POMC neurons
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1436 - R1444.
[Abstract] [Full Text] [PDF]
K. E. Wortley, G.-Q. Chang, Z. Davydova, and S. F. Leibowitz
Peptides that Regulate Food Intake: Orexin gene expression is increased during states of hypertriglyceridemia
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1454 - R1465.
[Abstract] [Full Text] [PDF]
D. Georgescu, V. Zachariou, M. Barrot, M. Mieda, J. T. Willie, A. J. Eisch, M. Yanagisawa, E. J. Nestler, and R. J. DiLeone
Involvement of the Lateral Hypothalamic Peptide Orexin in Morphine Dependence and Withdrawal
J. Neurosci., April 15, 2003; 23(8): 3106 - 3111.
[Abstract] [Full Text] [PDF]
Mechanisms of Weight Gain Due to Antipsychotic Medications
Journal Watch Psychiatry, September 4, 2002; 2002(904): 3 - 3.
[Full Text]
|
|
|
|
 |
|